Molecular magnetic resonance imaging of brainâ€“immune interactions by Maxime Gauberti et al.
REVIEW ARTICLE
published: 27 November 2014
doi: 10.3389/fncel.2014.00389
Molecular magnetic resonance imaging of brain–immune
interactions
Maxime Gauberti, Axel Montagne, Aurélien Quenault and Denis Vivien*
Inserm, Inserm UMR-S U919, Serine Proteases and Pathophysiology of the Neurovascular Unit, Université de Caen Basse-Normandie – GIP Cyceron,
Caen, France
Edited by:
Arthur Liesz, Institute for Stroke and
Dementia Research – University
Hospital Munich, Germany
Reviewed by:
Xin Cheng, Huashan Hospital Fudan
University, China
Marco Duering,
Ludwig-Maximilians-University
Munich, Germany
*Correspondence:
Denis Vivien, Inserm, Inserm UMR-S
U919, Serine Proteases and
Pathophysiology of the Neurovascular
Unit, Université de Caen
Basse-Normandie – GIP Cyceron,
Boulevard Henri Becquerel, BP5229,
14074 Caen, France
e-mail: vivien@cyceron.fr
Although the blood–brain barrier (BBB) was thought to protect the brain from the effects
of the immune system, immune cells can nevertheless migrate from the blood to the
brain, either as a cause or as a consequence of central nervous system (CNS) diseases,
thus contributing to their evolution and outcome. Accordingly, as the interface between
the CNS and the peripheral immune system, the BBB is critical during neuroinﬂammatory
processes. In particular, endothelial cells are involved in the brain response to systemic
or local inﬂammatory stimuli by regulating the cellular movement between the circulation
and the brain parenchyma. While neuropathological conditions differ in etiology and in the
way in which the inﬂammatory response is mounted and resolved, cellular mechanisms
of neuroinﬂammation are probably similar. Accordingly, neuroinﬂammation is a hallmark
and a decisive player of many CNS diseases.Thus, molecular magnetic resonance imaging
(MRI) of inﬂammatory processes is a central theme of research in several neurological
disorders focusing on a set of molecules expressed by endothelial cells, such as adhesion
molecules (VCAM-1, ICAM-1, P-selectin, E-selectin, …), which emerge as therapeutic
targets and biomarkers for neurological diseases. In this review, we will present the most
recent advances in the ﬁeld of preclinical molecular MRI. Moreover, we will discuss the
possible translation of molecular MRI to the clinical setting with a particular emphasis
on myeloperoxidase imaging, autologous cell tracking, and targeted iron oxide particles
(USPIO, MPIO).
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INTRODUCTION
Brain–immune interactions play a central role in acute neurolog-
ical disorders including ischemic stroke, intracranial hemorrhage
and traumatic brain injury (Wang and Dore, 2007; Iadecola and
Anrather,2011;Woodcock andMorganti-Kossmann,2013). Given
the proven and putative clinical beneﬁts of modulating brain–
immune interactions, non-invasive methods aimed at imaging the
molecular players involved in these processes have been the subject
of numerous studies. The most promising approaches to visual-
ize brain–immune interactions are magnetic resonance imaging
(MRI), positron emission tomography (PET), single photon emis-
sion computed tomography (SPECT), and optical imaging (in
preclinical studies). Only molecular MRI combines fast acqui-
sition time, wide clinical availability and acceptable safety proﬁle
for repeated scanning. However, molecular MRI lacks sensitiv-
ity compared to PET or SPECT. Notably, recent developments
in the ﬁeld of MRI contrast agent dramatically improved MRI
sensitivity and allowed, for the ﬁrst time, reliable imaging of the
proteins involved in brain immune interactions with high spatial
and temporal resolutions.
Brain–immune interactions occur all over the time course of
acute neurological diseases. Upon injury, endothelial cells of the
cerebrovasculature become activated and release the content of
their Weibel-Palade bodies. This leads to P-selectin exposure on
their surface and subsequent adhesion of neutrophils through
P-selectin – P-selectin Glycoprotein Ligand-1 (PSGL-1) interac-
tions (Ley et al., 2007). In parallel, in the brain parenchyma,
an early phase of microglial activation is followed by a local
inﬂammatory response (including microgliosis, astrogliosis, and
cytokines/chemokines secretion) which sustains the activation
state of brain endothelial cells. Expression of E-selectin, intercel-
lular adhesion molecule-1 (ICAM-1), and vascular cell adhesion
molecule-1 (VCAM-1) on the luminal endothelial surface allows
adhesion and subsequent diapedesis of systemic immune cells
inside the brain parenchyma. These inﬁltrated cells further
enhance the inﬂammatory reaction in order to ﬁght potential
pathogens and clear cellular debris. To this aim, they secrete
numerous cytokines/chemokines, proteolytic enzymes, and per-
oxydases (includingmyeloperoxidase,MPO).Neuroinﬂammation
is also deemed necessary for the post-injury reparation phase
that can last for weeks after the initial brain insult (Kyritsis
et al., 2012; Tobin et al., 2014). This phase involves neurogen-
esis, dendritogenesis, oligodendrogenesis, axon sprouting, and
matrix remodeling to restore tissue integrity (Peruzzotti-Jametti
et al., 2014). All these mechanisms are common to acute brain
injuries (including ischemia, hemorrhage, and trauma), neuroin-
ﬂammatory (including multiple sclerosis) and neurodegenerative
disorders (Schwartz et al., 2013). However, discrepancies exist in
terms of kinetic, localization, and intensity of the inﬂammatory
responses.
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Improvement in our general knowledge of the brain–immune
interactions taking place during acute neurological disorders
revealed new potential therapeutic targets. Nevertheless, the suc-
cesses and failures of immunomodulatory treatments for acute
brain injury remind us that precise characterization of the inter-
play between leukocytes, endothelial adhesion molecules, glial,
and neuronal cells is mandatory for efﬁcient design of therapeu-
tic strategies targeting brain–immune interactions. For instance,
Natalizumab, a monoclonal antibody targeting the interaction
between very late antigen 4 (VLA-4) and VCAM-1, has been suc-
cessfully developed as a treatment for multiple sclerosis (Miller
et al., 2003). In contrast, Enlimomab, a monoclonal antibody tar-
geting neutrophils diapedesis by ICAM-1 blockade, has failed in
phase III trials involving ischemic stroke patients (Enlimomab
Acute Stroke Trial, 2001), despite preclinical evidence of its potent
neuroprotective effects (Matsuo et al., 1994; Connolly et al., 1996).
In fact, contrary to what initially thought, a recent study demon-
strated that neutrophils do not reach the brain parenchyma
after stroke in humans (Enzmann et al., 2013). Moreover, it
becomes now clearer that one size does not ﬁt all: variability in
individual inﬂammatory response following acute brain injury
suggests that modulation of brain–immune interaction may prove
beneﬁcial in some individuals but not in others. Consider-
ing that blockade of leukocytes subsets may also be associated
with impaired host defense against pathogens, adequate selec-
tion of patients should be performed before administration of
immunomodulatory drugs.
In this context, molecular MRI appears highly promising
to select patient candidates for immunomodulatory treatments,
monitor treatment efﬁciency, and more generally improve our
knowledge on brain–immune interactions in human patients. The
purpose of this review is to present recent advances in the ﬁeld of
molecular MRI of brain–immune interactions. After presentation
of the theoretical bases of molecular MRI and of the brain-speciﬁc
issues of this non-invasive method, we will present recent studies
relevant to brain–immune interactions after acute cerebral injury
with a particular focus on MPO imaging, autologous cell tracking,
unlabeled ultrasmall superparamagnetic particles of iron oxide
(USPIOs), targeted USPIOs, and targeted microsized particles of
iron oxide (MPIOs; Figure 1).
BASIS OF MOLECULAR MAGNETIC RESONANCE IMAGING
Magnetic resonance imaging signal is generated by the magneti-
zation of the hydrogen nuclei (protons) from biological tissues.
Basically, two different classes of MRI contrast agents are avail-
able: T1 contrast agents increase the signal on T1-weighted images
by shortening the spin-lattice relaxation time (T1 constant). T2
and T2∗ contrast agents decrease the signal on T2- and T2∗-
weighted images by both shortening the spin–spin relaxation time
(T2 constant) and dephasing adjacent protons (by modiﬁcation
of their precession angular velocity). Therefore, depending on the
contrast material injected, a molecular target can be revealed by
an increase (paramagnetic T1 contrast agent,mainly Gadolinium-
based) or a decrease (superparamagnetic T2 or T2∗ contrast agent,
mainly iron-oxide-based) in theMRI signal (Figure 2). Newmeth-
ods of molecular MRI have been recently developed [such as
chemical exchange saturation transfer (CEST), positive contrast
imaging or MRI of non-hydrogen nuclei] but they still present a
FIGURE 1 | Main targets of molecular imaging. USPIO, ultrasmall particles of iron oxide; MPIO, microsized particles of iron oxide; MPO, myeloperoxidase;
VCAM-1, vascular cell adhesion molecule-1; ICAM-1, intercellular adhesion molecule-1.
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FIGURE 2 | Schematic representation of the effects of different contrast agents on water magnetization in biological samples.TR, repetition time; TE,
EchoTime.
limited sensitivity compared tomore conventionalmethods. Their
development remains however of great interest since such con-
trast agents could allow imaging multiple targets simultaneously
(Woods et al., 2006).
Independently of the contrast agent, the general concept of
molecular MRI is to target a contrastophore (either Gadolinium-
or Iron-oxide-based) to a protein of interest using a targeting
moiety (pharmacophore). This targeting moiety can be either
a speciﬁc ligand (such as a protein, an antibody or a specif-
ically designed peptide) or a substrate of an enzyme which
can accumulate in the regions where its corresponding enzyme
is overexpressed/active. For instance, VCAM-1 imaging can be
performed using microparticles of iron oxide (MPIO, the con-
trastophore) coupled tomonoclonal antibodies targetingVCAM-1
(the pharmacophore). After intravenous injection, this agent
binds to endothelial VCAM-1 and induces T2∗ effects leading
to decreased signal on T2∗-weighted images (i.e., signal voids)
in regions presenting activated endothelial cells (McAteer et al.,
2007).
The concentration of contrast material is one of the most
important limits of molecular MRI. Indeed, whereas PET can
detect β+ emitting atoms at picomolar concentration, MRI using
classical Gadolinium-based contrast agent (GBCA) presents a sen-
sitivity in the micromolar range. To overcome this limitation,
contrast agent carrying large payload of gadolinium or iron oxide
have been developed, including paramagnetic liposomes and iron
oxide particles (Figure 3). In this regard, MPIOs (1–4 μm in
diameter) are particularly interesting since even a single particle
can be detected by high-ﬁeld MRI at high resolution (Montagne
et al., 2012). After binding to its target, targeted MPIOs induce
dephasing of the surrounding protons, leading to strong and large
T2∗ effects, up to 50 times larger than the original particle size
(∼50 μm; Shapiro et al., 2006). At equal concentrations of iron,
MPIOs inducemuch stronger T2∗ effects thanUSPIOs (10–50 nm;
Montagne et al., 2012). This new generation of contrastophores is
therefore especially efﬁcient for the detection of targets present at
low concentration on the surface of brain endothelial cells.
The use of high resolution and strongly T2∗-weighted images
to improve MRI sensitivity may also favor endogenous contrasts
and false positive detection of iron oxide particles. In particular,
hemorrhages and blood oxygen level dependent (BOLD) effects
induce signal voids on T2∗-weighted images which are compa-
rable to MPIO-induced signal void and could therefore lead to
false positive results. To overcome this, we demonstrated in a
recent study in mice that a short preparation time (30 min)
of normobaric hyperoxia can be sufﬁcient to transform deoxy-
hemoglobin (paramagnetic) into oxyhemoglobin (diamagnetic)
by increasing the tissular concentration of O2 (Gaberel et al.,
2013). Thus, the susceptibility effect of endogenous blood is
blunted, allowing observing changes in signal intensity that are
speciﬁc to the contrast agent injected. Importantly, this prepa-
ration period of hyperoxia did not impair behavioral testing in
mice presenting intracranial hemorrhages suggesting that this
strategy is safe. Further studies should look at the effect of nor-
mobaric hyperoxia on T2∗-weighted images in larger animals and
humans.
BRAIN SPECIFIC ISSUES IN MOLECULAR IMAGING
Thepresence of theBBB represents a challenge formolecular imag-
ing of the brain. Indeed, to reach parenchymal targets, contrast
agents should be able to cross the BBB. To date, there is no con-
trast agent able to cross the BBB in sufﬁciently large quantities
to induce signiﬁcant changes in MRI signal. Therefore molecu-
lar imaging of the brain is limited to endothelial proteins (such
as VCAM-1, ICAM-1, E-selectin, and P-selectin), to diseases with
compromised BBB (such as stroke, multiple sclerosis or severe
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FIGURE 3 | Main characteristics of the most widely used contrastophores.
traumatic brain injury) and to cells capable of crossing the BBB
(such as monocytes). The purpose of this paragraph is to present
the main issues related to each imaging targets that should be
kept in mind when performing molecular MRI of brain–immune
interactions.
Endothelial proteins are targets easily accessible to large
contrast-carrying particles and have been accordingly success-
fully imaged using different contrast agents (from small GBCA
to large iron oxide particles). The ﬁrst issue related to imaging
of endothelial targets is the requirement of a high afﬁnity of the
pharmacophore for its target because of the force exerted by the
blood ﬂow. These shear forces promote detachment of the contrast
agent from the endothelial wall and thus limit the time window
for imaging (von Zur Muhlen et al., 2008). Moreover, since MRI
should be performed after complete washout of the contrast agent
from the blood, a short half-life of the contrast agent is required
to allow imaging before its detachment from the endothelium.
Therefore, for efﬁcient detection of endothelial targets, the con-
trast agent should combine a high afﬁnity for its target and a short
half-life. Importantly, to avoid false positive ﬁndings, the molecu-
lar weight of the contrast agent should be large enough to prevent
passive extravasation across the BBB. Of note, once in the brain
parenchyma, low molecular weight compounds are able to spread
throughout the brain thanks to the glymphatic system (Gaberel
et al., 2014).
Issues related to imaging of intraparenchymal targets in condi-
tions of injured BBB are numerous. First, the molecular weight of
the contrast agent should be low to maximize its passive extravasa-
tion through the BBB. The drawback is that this limits the quantity
of contrast material carried by contrast agent molecules. In fact,
onlyGBCAhave been used for this purpose. Second, the speciﬁcity
of this method is limited: even in the absence of the molecular tar-
get, the contrast agent accumulates in an unspeciﬁc manner in the
brain regionswith BBB leakage. Activatable contrast agents such as
bis-5HT-DTPA(Gd) (a substrate for MPO) might partially over-
come this limitation (Breckwoldt et al., 2008). Enzyme processing
induces oligomerization and protein binding of the contrast agent
leading to accumulation and increased T1 effect. Indeed, the T1
effect of paramagnetic contrast agents increases in parallel with
the molecular weight due to limitation of motion of the Gadolin-
ium atom. Therefore processed contrast agent molecules induce
more important changes in signal intensity, allowing reduction
of the injected dose and thus reducing unspeciﬁc signals. Never-
theless, interpretation of changes in signal intensity after contrast
agent injection is difﬁcult since it depends both on the importance
of the BBB leakiness and on the concentration of the molecular
target. Accordingly, post-contrast images would be similar in a
condition of severe BBB impairment without MPO secretion and
in a condition of mild BBB impairment with MPO secretion. This
lack of speciﬁcity remains one of the main limitations of molec-
ular MRI of parenchymal targets, even using activatable contrast
agents.
Imaging of leukocyte diapedesis is the third strategy devel-
oped for molecular MRI of the brain. Accumulation of leucocytes
(especially blood-derived monocytes/macrophages) in the brain
is a speciﬁc feature of neuroinﬂammation and then represents an
attractive target for molecular imaging. However, this is a rel-
atively delayed event after injury and requires a delay between
injection of the contrast agent and imaging in order to allow its
uptake and accumulation of leukocytes within the parenchyma.
The prototypic contrast agents used to label leukocytes are unla-
beled ultrasmall particles of iron oxide (USPIO; Corot et al.,
2004). These small-sized iron-oxide-based contrast agents are
internalized by circulating monocytes after intravenous injection.
USPIOs-labeled monocytes are then detected by MRI once they
have accumulated in the inﬂamed region of the brain. The delay
between injection and imaging is usually long, about 24 h, lim-
iting the interest of such contrast agents in the acute phases.
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Moreover, the relative amount of contrast agent eventually reach-
ing the parenchyma is directly dependent on the number of
monocytes entering the brain, thus limiting the sensitivity of
the method. The other limitation is the possibility of false pos-
itive ﬁndings in case of BBB leakage, since USPIO readily crosses
the BBB after stroke as well as in active plaques of multiple scle-
rosis for instance (Desestret et al., 2009). The different contrast
appearances and the inﬂuence of the BBB status are illustrated on
Figure 4.
In the next paragraphs, we will present the main studies
reporting the use of molecular MRI for studying brain–immune
interactions after acute cerebral injury (Table 1).
MYELOPEROXIDASE IMAGING
Myeloperoxidase is an abundant enzyme expressed by activated
inﬂammatory cells of the myeloid lineage (Bradley et al., 1982),
especially macrophages, monocytes, and neutrophils. MPO can
induce endothelial dysfunction and increased inﬂammation due
to upregulation of inducible nitric oxide synthase and carbamy-
lation of lipoproteins. Indeed, MPO interacts with hydrogen
peroxide to generate highly reactive species, such as OCl−, O2−,
ONOO− that can covalently modify lipids, causing further local
tissue damage and perpetuating the inﬂammatory cascade (Klinke
et al., 2011). MPO-generated free radicals induce apoptosis and
nitro-tyrosination of proteins (Heinecke, 2002). Therefore, MPO
is included in a complex cascade of inﬂammatory events involv-
ing different types of cells and molecules. Accordingly, molecular
imaging of MPO could help detecting areas of brain inﬂammation
(endogenous microglia and inﬁltrated macrophages/neutrophils)
in several CNS disorders.
The idea to non-invasively “image” inﬂammation by target-
ing MPO expression/activity had ﬁrst been investigated by Chen
et al. (2004), in a key article in which the authors synthesized
and tested a series of activatable paramagnetic MR contrast
agents. After several developments, the same team selected a
candidate, called bis-5HT-DTPA(Gd) (Querol et al., 2005, 2006).
FIGURE 4 | Schematic representation of the effect of different
contrast agents on brain MRI of a rodent with inflammation in
the right striatum. The inﬂammatory region with impaired BBB is
represented in dark red, whereas the inﬂammatory region without BBB
impairment is in light red. Time-dependent signal changes after contrast
agent injection are represented vertically. In contrast to the signal
changes induced by targeted MPIOs which are independent of the BBB
status, the contrast enhancement induced by other contrast agents is
not inﬂammation speciﬁc and strongly depends on the permeability of
the BBB.
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Basically, a speciﬁc substrate of MPO (5-hydroxytryptamide)
is associated with a Gadolinium-based contrastophore which is
responsible for the paramagnetic effect. In the presence of MPO,
the 5-hydroxytryptamide moiety of bis-5HT-DTPA(Gd) is oxi-
dized and radicalized by hydrogen peroxide. The radicalized
bis-5HT-DTPA(Gd) molecule can react with another radicalized
bis-5HT-DTPA(Gd) molecule to form a polymer of up to ﬁve
subunits leading to an ampliﬁcation of the enzymatic reaction. In
mice, the activated agent can also bind to proteins within inﬂam-
matory sites, trapping the agent, further increasing its molecular
weight, and increasing the signal intensity on T1-weighted MRI
(Chen et al., 2006). Converted products are locally retained, so that
pharmacokinetics properties are improved: prolonged enhance-
ment can be detected for up to 60 min at sites of increased MPO
activity. The speciﬁcity of Bis-5HT-DTPA(Gd) was demonstrated
using a substrate not speciﬁc for MPO (di-tyrosine), a pharma-
cological inhibitor of MPO (ABAH) or MPO knockout mice.
In conclusion, bis-5HT-DTPA(Gd) appeared as a biocompatible
agent with good sensitivity and speciﬁcity. Accordingly, this agent
has been tested in several pathological contexts.
In experimental autoimmune encephalomyelitis (EAE)
induced with synthetic proteolipid protein, a model of multiple
sclerosis, MPO imaging has been tested for its ability to detect
active plaques before clinical symptoms appearance in mice. The
authors found that bis-5HT-DTPA allows detection of MPO, as a
surrogate marker of the appearance and size of active plaques,
and was correlated to clinical grading (Chen et al., 2008). In
the same model of multiple sclerosis, another group used MPO
imaging as an objective evidence of the therapeutic efﬁciency of
an inhibitor (ABAH) of MPO. Bis-5HT-DTPA-based signals on
imaging were smaller and matched with less demyelination and
reduced severity of symptoms (Forghani et al., 2012). A study
proposed that multiple sclerosis could be due to chronic cere-
brospinal venous insufﬁciency (CCVI). However, bis-5HT-DTPA
imaging performed in EAE mice subjected to ligature of the jugu-
lar vein to induce CCVI invalidated this hypothesis. Indeed, the
authors did not observe any effect of CCVI on the correlation
between MPO activity and neuroinﬂammation, demyelination,
or clinical signs (Atkinson et al., 2012). Whether these negative
results could be explained by the low sensitivity of this imaging
method to detect subtle inﬂammatory changes remains, however,
unclear.
Bis-5HT-DTPA has also been used in a model of transient focal
stroke (transient mechanical vascular occlusion model during
30 min). In this study, MPO imaging correlated with infarct size,
and the authors hypothesized that MPO imaging could be used to
select and stratify patients for clinical trials of therapies targeting
inﬂammation (Breckwoldt et al., 2008). In an experimental model
of common carotid artery aneurysm induced by elastase, MPO
imaging was shown to be valuable to identify unstable aneurysms,
at risk of subsequent rupture (DeLeo et al., 2009).
Myeloperoxidase imaging has thus proven relevant to diagnose,
predict, or evaluate therapeutic efﬁciencies in several models of
CNS disorders. However, as already mentioned, it is widely recog-
nized that these MRI techniques have limitations because contrast
enhancement reﬂects breakdown of the BBB with leakage of para-
magnetic chelates rather than active inﬂammation, and the two
may not always correspond. Another potential limitation is that
MPO imaging does not discriminate between MPO secreted from
resident microglia, inﬁltrated macrophages or neutrophils.
Finally, the activated MPO sensor is cleared from the brain
within 6h after administration; the protein-bound, activatedMPO
agents are likely digested and released by proteases that are present
at sites of inﬂammation (Querol et al., 2006).
Therefore, enzymatic imaging targeting MPO points to an
interesting technology for non-invasive conﬁrmation of active
inﬂammatory lesions in brain disease. This could potentially not
only improve disease diagnosis and treatment assessment in the
clinical setting, but may also lead to a better evaluation of drug
development and clinical trials of new therapies. This method is,
however, impaired by its lack of speciﬁcity due to passive extrava-
sation and accumulation of the unprocessed contrast agent, which
contributes signiﬁcantly to MRI signal changes.
IMMUNE CELL TRACKING
Administration of exogenously labeled cells and subsequent track-
ing by non-invasive imaging has encountered numerous successes
inmolecular imaging of brain immune interactions. Unlike in vivo
labeling of circulating cells using untargeted USPIO, this method
has the advantage of a higher speciﬁcity since the contrast agent
particles are clustered inside immune cells and are thus less suscep-
tible to reach the brain in an unspeciﬁc manner (such as passive
extravasation through a leaky BBB). Moreover, it allows direct
imaging of brain–immune interactions as a whole, taking into
account all the processes involved in the regulation of endothe-
lial binding and blood to brain diapedesis of autologous cells. The
basis of this method is to harvest autologous cells (most frequently
leukocytes) and to label them with a high payload of contrast
agent without impairing their ability to reach the CNS. Several
labeling methods have been performed, based either on phago-
cytic uptake of contrast agent particles or on direct transfection
of the cells with iron particles or Gadolinium using permeating
agents.
One of the ﬁrst studies investigating the use of systemi-
cally injected autologous labeled cells for molecular imaging
demonstrated that rat bone marrow stromal cells were able to
invade a photochemically induced brain lesion 7 days after intra-
venous injection (Jendelová et al., 2004). Later, Stroh et al. (2006)
labeled spleen-derived mononuclear cells (MNCs) with very small
superparamagnetic iron-oxide particles and transfused them into
recipient mice subjected to transient ischemic stroke (ﬁlament
model). Areas of signal hypointensities started to appear 24–48 h
after intravenous injection of MNCs and corresponded to grafting
of the cells in the ischemic lesion.
A similar method has been used by Anderson et al. (2004)
in a mouse model of EAE by adoptive transfer of encephalito-
genic T cells. They labeled endosomes from murine T-cells ex
vivo using polylysine and ferumoxide and injected the labeled cells
intraperitoneally in recipientmice. The authors were able to detect
both ex vivo and in vivo the labeled cells in the lumbar spinal
cord of EAE mice after the onset of clinical signs. Interestingly,
the primary location of the encephalitogenic T-cells revealed by
molecular MRI in this study was later conﬁrmed by Arima et al.
(2012), who demonstrated that autoreactive T cells access the CNS
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via the ﬁfth lumbar spinal cord. Other immune-related cell-types
can be labeled and subsequently imaged using the same label-
ing strategy, such as bone marrow-derived cells (Anderson et al.,
2005).
Besides these proof-of-concept studies, molecular imaging of
exogenously labeled cells allows to easily investigate the mecha-
nisms driving the interactions between circulating cells and the
brain endothelium. For instance, Gorelik et al. (2012) demon-
strated in rats that iron oxide labeled glial-precursor cells can be
targeted to the brain by the virtue of the interaction between circu-
lating cell expressed VLA-4 and endothelial VCAM-1. Using MRI,
they compared the efﬁciency of brain delivery of VLA-4 trans-
fected and control glial precursor cells with or without VCAM-1
overexpression in the brain induced in situ by lipopolysaccha-
ride injection. They found that brain delivery was dramatically
enhanced when the injected cells and the brain expressed VLA-4
and VCAM-1, respectively. This kind of clever experiment can be
performed using various types of circulating cells to improve our
knowledge of brain–immune interactions.
The main limitation of this method is its reduced applicabil-
ity for diagnostic purposes in humans. Although radiolabeling of
autologous cells has been used successfully for imaging inﬂamma-
tion using SPECT and PET (Pulli and Chen, 2014), the limited
sensitivity of MRI requires high payload of contrast agent per cell
and a large amount of cells to be reinjected to achieve reliable imag-
ing. Moreover, labeled cells might lose their iron oxide particles
or die leading to false negative results. Another limitation is the
effects of the labeling procedure including cell collection, puriﬁca-
tion, iron-oxide particles engulfment, and reinjection which can
all inﬂuence the phenotype of the cells. To make this procedure
faster and overcome some of its drawbacks, endogenous label-
ing of the monocyte/macrophage lineage using USPIOs has been
developed.
UNLABELED USPIO
Unlabeled USPIOs are virus-sized molecules with a very long
blood clearance time (over 24 h). Iron oxide agents have greater
contrast sensitivity compared to GBCA, generating signal voids on
MRI, due to shortening of T2 and T2∗ relaxation times. A large
range of sizes exist, from nano- to micron-sized iron oxide parti-
cles. USPIOs are among themost famousMR contrast agents, with
a range in size from 10–50 nm, and should be differentiated from
the larger SPIOs and MPIOs with diameters about 50–300 nm and
0.9–5μm, respectively. Iron oxide particles are based onmagnetite
(Fe3O4), and are usually encased in polysaccharide, synthetic poly-
mers, or monomer coatings (Thorek et al., 2006; Laurent et al.,
2008). The utility of these particles as MRI contrast agents has
been studied for more than two decades and the list of available
agents is still expanding.
Ultrasmall superparamagnetic particles of iron oxides are read-
ily internalized by phagocytic cells such as the Kupffer cell of
the liver, circulating monocytes/macrophages and mononuclear
T cells, as well as reactive astrocytes, microglia, and dendritic
cells within the CNS. The USPIOs are cleared from the circula-
tion primarily by the reticulo-endothelial system (Bourrinet et al.,
2006); these properties (i.e., degree of cellular uptake and rate of
clearance) are dependent on size, coating, and method of delivery.
The USPIOs ferumoxytol (Feraheme®, AMAG Pharmaceuti-
cals Inc) was initially approved for iron-replacement therapy in
patients with chronic renal failure. However, ferumoxytol has also
been investigated in humans for variousCNS imaging applications
(Neuwelt et al., 2007), as well as ferumoxtran-10 (Manninger et al.,
2005; Saleh et al., 2007) and SHU 555 C (Vellinga et al., 2008) to
name a few. Ferumoxytol, in particular, is attractive as an MRI
contrast agent because it is approved for use in humans and it is
safe in patients with chronic kidney disease. It can be given as a
bolus for ﬁrst-pass perfusion imaging and at a later time point
(e.g., 24 h) ferumoxytol accumulation is obvious in regions of
BBB dysfunction that may be related to inﬂammation from any
cause.
Several groups have shown thatmolecular imaging is an impor-
tant newdiagnostic tool for studying in vivo cellular andmolecular
biology across a wide range of disciplines, especially regarding
inﬂammatory processes and associated immune cells, in both
humans and animal models. Such applications may be relevant
for earlier disease detection, more precise prognosis, personalized
treatment strategies,monitoring of treatment efﬁciency andﬁnally
to improved our understanding of how cells behave and interact
in their microenvironment in vivo (Thorek et al., 2006).
The most common strategy for cellular MRI of neuroinﬂam-
mation involves tagging of circulating monocytes by systemic
injection of iron oxide nanoparticles. In 2001, Rausch and cowork-
ers ﬁrst developed this approach in a stroke model in rats, where
a single dose of USPIOs (Sinerem®, AMAG Pharmaceuticals Inc)
was injected intravenously 5 h post-onset (Rausch et al., 2001).
An accumulation of USPIOs was shown in the periphery of the
lesion 24 h post-injection. At day 7, the USPIOs signal was still
present and spread out within the lesion area, spatially correlat-
ing with areas displaying activated macrophages. Several groups
have used a similar protocol to assess the spatiotemporal proﬁle of
monocyte inﬁltration in various stroke models in rodents (Klein-
schnitz et al., 2003; Saleh et al., 2004b; Wiart et al., 2007; Kim et al.,
2008). These studies raise an interesting technical point related to
the USPIOs uptake by circulating white blood cells and, therefore,
the USPIOs blood half-life. It has been shown that phagocytic
cellular uptake of iron oxide increases with particle size (Daldrup-
Link et al., 2003; Matuszewski et al., 2005). With a hydrodynamic
diameter of 10 to 50 nm, USPIOs are less efﬁciently phagocytosed
than SPIOs with sizes of 50–300 nm. The maximum intracellu-
lar iron oxide concentration of in vitro-labeled, isolated human
macrophages is 50 pg iron/cell for the SPIOs ferucarbotran (Reso-
vist®,Bayer Schering PharmaAG) whereas for USPIOs SHU 555 C
(Supravist®, Bayer Schering Pharma AG), it is below 8 pg iron/cell
(Metz et al., 2004). Besides the particle size of the iron oxide,
phagocytic uptake is also dependent on nanoparticle surface prop-
erties (e.g., neutral versus charged). Numerous studies employed
neutrally charged dextran-coated USPIOs (e.g., Sinerem®) with
a long blood half-life compared to larger ferumoxides, such as
dextran- (Endorem®in Europe, Feridex®in the USA) or anionic-
carboxydextran- (Resovist®) coated SPIOs (Weissleder et al., 1989;
Rausch et al., 2002; Briley-Saebo et al., 2006). Thus, the USPIOs
extended blood half-life is assumed to promote the uptake by cir-
culating cells. Furthermore, pharmacological strategies, using the
protamine sulfate peptide, may be also used to enhance USPIOs
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uptake, as reported in vitro (Arbab et al., 2004) and in vivo in rats
(Wu et al., 2007).
Although internalization of contrast agents in activated
macrophages and its correlation with MRI contrast have been
reported in different studies, there is still debate on the speciﬁcity
of the observedMRI contrast. For instance, some studies suggested
that USPIOs-induced contrast could be non-speciﬁc, i.e., due to a
passive diffusion of iron particles through the BBB (Kleinschnitz
et al., 2003; Saleh et al., 2004a; Denes et al., 2007; Nighoghossian
et al., 2007; Saleh et al., 2007). The passive diffusion is patently
increased because of a disrupted BBB in a context of stroke
(Dijkhuizen et al., 2002). To distinguish between USPIOs passive
diffusion in the brain parenchyma and inﬂammation, USPIOs-
based MRI have been combined with Gadolinium-enhanced MRI
to correlate USPIOs accumulation and BBB integrity, both in ani-
mal models and in humans (Kleinschnitz et al., 2003; Saleh et al.,
2004a, 2007; Denes et al., 2007; Nighoghossian et al., 2007). As an
alternative to the approach of labeling within the bloodstream,
blood cells may also be extracted, labeled in vitro and then rein-
jected as presented above (exogenously labeled cells). This would
avoid non-speciﬁc free iron particles leakage over the BBB and/or
entrapment in the vasculature (Stroh et al., 2006; Oude Engberink
et al., 2008). One of the latest unlabeled USPIO is P904 (Guerbet),
for which phase I clinical trial has been initiated, demonstrating a
signiﬁcantly higher uptake by macrophages because of their pegy-
lated coating compared to dextran-coated USPIOs (Yancy et al.,
2005; Sigovan et al., 2009).
Despite the technical issues described above, this cellular MRI
approach has given encouraging results to pursue further inves-
tigations. Non-targeted USPIOs may also be interesting in the
ﬁeld of atherosclerosis (including intracranial atherosclerosis),
as suggested by experimental in vivo studies in hyperlipidemic
rabbits (Ruehm et al., 2001; Briley-Saebo et al., 2008) and in
humans (Kooi et al., 2003; Trivedi et al., 2006). These groups
have shown non-targeted USPIOs accumulation in atheroscle-
rotic plaques rich in macrophages, both in animals and humans.
Additionally, USPIOs were shown to localize to atherosclerotic
plaques-containing macrophages in apolipoprotein E knockout
mice (Morris et al., 2008). Using the same transgenic model, a p38
MAP kinase inhibitor has been shown to decrease USPIOs uptake
by atherosclerotic plaques, which correlated with a reduction in
macrophage activity by histology.
TARGETED USPIO
To counteract potential problems related to untargeted-USPIOs,
targeted-nanoparticles of iron oxide have been developed to
image neuroinﬂammation. VCAM-1 which promotes mono-
cytes recruitment to the vascular wall and subsequent lesion
development, is a promising marker for molecular imaging of
cerebrovascular inﬂammation in several CNS disorders, since it
is not constitutively expressed in normal vessels but is rapidly
up-regulated on activated vascular endothelial cells (Davies et al.,
1993; Cybulsky et al., 2001). On this basis, several generations of
VCAM-1 targeted (using monoclonal antibodies or peptides gen-
erated by phage display) iron oxide nanoparticles conjugated with
ﬂuorescent molecules (Cy5.5) have been produced and applied
in mouse models of acute inﬂammation and atherosclerosis
(Kelly et al., 2005; Tsourkas et al., 2005; Nahrendorf et al., 2006).
Molecular imaging of endothelial activation has been performed
using USPIO labeled with a speciﬁcally designed targeting moi-
ety consisting in a small peptide which triggers internalization
of the USPIO by activated endothelial cells (Kelly et al., 2005).
This ampliﬁcation strategy allowed efﬁcient intravitalmicroscopic
detection of the particles but thismethod lacked sensitivity for reli-
able in vivo imaging. Moreover, USPIOs conjugated to a VCAM-1
speciﬁc cyclic peptide (P03011 or R832, Guerbet) have recently
been developed for in vivo detection of inﬂamed vessels in early
and advanced atherosclerotic plaques by ultra-high ﬁeld strength
MRI (Burtea et al., 2012; Michalska et al., 2012), as well as in
an ischemic stroke model in mice (Fréchou et al., 2013). Again,
the sensitivity and speciﬁcity of VCAM-1 imaging using these
USPIO-based strategies remained limited.
Among the different target of labeled USPIOs, E-selectin has
been extensively studied in peripheral inﬂammation in mice (ear
inﬂammation, muscle inﬂammation . . .; Reynolds et al., 2006).
Selectins have also been investigated as target for MR molecu-
lar imaging of inﬂammation owing to their role in recruiting
immune cells (i.e., leukocytes) to the vascular wall. Platelet-
selectin (P-selectin), for example, is involved in early events of
the inﬂammatory pathway, which make them an ideal target for
early diagnosis of vascular inﬂammation. In addition, its base-
line expression is near zero, which enables subtle changes to
be detected in the vascular wall. E-selectin targeting is usually
achieved using a Sialyl-Lewis X targeting moiety (USPIO-sLeX;
Radermacher et al., 2009). But other USPIOs have been developed
with peptidic (Chapon et al., 2009) or F(ab’) – based targeting
moieties (Reynolds et al., 2006, Radiology). A study reported the
use of E-selectin targeted USPIOs to detect endothelial activation
in a mouse model of traumatic brain injury (Chapon et al., 2009).
However, the sensitivity achieved using this agent is limited and
does not allow reliable detection of brain E-selectin. A similar
approach with P-selectin as a target has been developed and tested
in an ischemic stroke model in mice (Jin et al., 2009), but presents
the same limit as E-selectin.
While targeted USPIO-based molecular imaging remains an
active ﬁeld of investigation, targeted-USPIOs may have potential
for toxicity, the sensitivity remains low even when ampliﬁcation
strategies are used and the speciﬁcity is impaired in condition of
BBB leakage because of passive USPIOs extravasation. In addition,
the long clearance time of USPIOs delays imaging until several
hours after administration, which is not ideal for clinical use. For
all these reasons, the feasibility of reliable in vivo molecular MRI
using targeted USPIOs remains elusive.
TARGETED MPIOs
Micro-sized particles of iron oxide have singular properties for
endothelial cell-speciﬁcmolecular imaging. First, theirmicron size
range allows endovascular speciﬁcity unlike USPIOs agents which
are susceptible to passive diffusion within the brain parenchyma,
passive accumulation in atherosclerotic plaques or even non-
speciﬁc macrophage uptake. Second, MPIOs convey a large
payload of iron oxide (usually 0.1–1.6 pg Iron/MPIO particle),
which is an order of magnitude larger than USPIOs contrast
agents, resulting in strong hypointense contrast effects that may
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extend up to 50 times the physical diameter of the particle. This
phenomenon, known as “blooming effect,” provides high sensitiv-
ity in vivo MRI detection, using only a small number of MPIO
particles (Shapiro et al., 2005, 2006; Heyn et al., 2006). Third,
MPIOs have very short blood half-life of 50–100 s (Ye et al., 2008;
Yang et al., 2010), allowing imaging immediately after injection
(Montagne et al., 2012; Gaberel et al., 2013; Gauberti et al., 2013).
Finally, MPIOs are readily functionalized by covalent conjugation
of ligands (monoclonal antibodies or their immunospeciﬁc frag-
ments F(ab), single chain antibodies or peptides derived from
phage display) to functional groups (amine, carboxyl acid or
p-toluene sulphydryl (tosyl)) on the MPIOs surface.
Limitations of these agents for CNS imaging are related to their
non-biodegradable coat and their potential iron toxicity. Indeed,
MPIOs’ coated-sheath includes inert polymers giving them a
non-biodegradable nature. Micro-sized particles may therefore
accumulate in the reticulo-endothelial system (McAteer et al.,
2007, 2008). To overcome this problem, more related to a clin-
ical use, development of biodegradable MPIOs is currently in
process, and some have already been developed (Nkansah et al.,
2011). Although commercially available MPIOs did not show any
side effects in cultured hepatocytes in terms of iron homeostasis
and cell survival (Raschzok et al., 2011), these particles might have
a potential long-term toxicity in humans due to the iron. Further-
more, the dose of iron used in most of experimental studies using
MPIOs is around 4 mg iron/kg (McAteer et al., 2007), which is
higher than the dose used in clinical practice to visualize tumors
with USPIOs (2.6 mg iron/kg; Will et al., 2006). In addition,
although their large size improves the speciﬁcity of MPIO-based
molecular MRI, they are not able to enter the brain parenchyma
and their targets are therefore limited to proteins expressed by the
endothelium such as cell adhesion molecules.
Microsized particles of iron oxides have been applied for imag-
ing of inﬂammation in many experimental studies, including
various animal models of CNS disorders. Due to its properties
mentioned earlier, VCAM-1 is an interesting biomarker in the
ﬁeld of molecular imaging and has been thoroughly studied over
the last years. For instance, MPIOs targeting VCAM-1 has been
studied in mouse models of acute cerebral inﬂammation (McA-
teer et al., 2007, 2012), chronic cerebral hypoperfusion (Montagne
et al., 2012), atherosclerosis (McAteer et al., 2008), strokes (Hoyte
et al., 2010; Gauberti et al., 2013), myocardial ischemia (Grieve
et al., 2013; von Elverfeldt et al., 2014), Alzheimer’s disease (Mon-
tagne et al., 2012), multiple sclerosis (Serres et al., 2011; Montagne
et al., 2012), and even in normal aging and systemic challenges
related to risk factors of CNS disorders (e.g., peripheral inﬂamma-
tion, ethanol consumption, and hyperglycemia; Montagne et al.,
2012).
Our group developed MPIOs conjugated to monoclonal
VCAM-1 antibodies (MPIOs-αVCAM-1) and used them for non-
invasive and high-sensitive in vivo detection of cerebrovascular
inﬂammation in pre-clinical models in mice (Montagne et al.,
2012). They provide higher sensitivity than previously reported
methods and molecular contrast agents (McAteer et al., 2007), and
are able to detect changes at a time that is otherwise undetectable
using conventional MRI. Using an antibody anti-VCAM-1 care-
fully preselected by histology and a small dose of MPIOs (e.g.,
1 mg iron/kg), we reported a dramatically higher sensitivity to
assess cerebrovascular cell activation compared to previously pub-
lished studies (Figure 5). In a model of acute inﬂammation in
mice receiving a microinjection of pro-inﬂammatory cytokine
tumor necrosis factor (TNF) into the right striatum, while the
left striatum was not injected and served as internal control,
we reported that in vivo T2∗-weighted MRI reveals a potent
hypointense contrast effect in the TNF injected hemisphere after
MPIOs-αVCAM-1 injection 24 h post-onset. No contrast effects
were seen in the non-injected hemisphere or in animals injected
with control MPIOs-IgG. Similarly, although pre-contrast MRI
images failed to reveal the ongoing pathology, contrast-enhanced
MRI using MPIOs-αVCAM-1 revealed hypoperfusion-triggered
CNS injury in vascular dementia, unmasked amyloid-induced
cerebrovascular activation in Alzheimer’s disease and allowed
monitoring of disease activity during EAE (Montagne et al.,
2012).
Other vascular biomarkers (mostly cell adhesion molecules)
have been studied over the last few years as potential targets forMR
molecular imaging of inﬂammation. ICAM-1, unlike VCAM-1, is
constitutively expressed in endothelial cells. ICAM-1 is neverthe-
less up-regulated during an inﬂammatory response. Deddens et al.
(2013) studied ICAM-1 up-regulation after stroke in mice using a
similar approach based on MPIOs coupled to anti-ICAM-1 anti-
bodies. Using the same custom contrast agent, this group also
showed ICAM-1 overexpression during EAE, providing an early
tracer of disease activity (Blezer et al., 2014). McAteer et al. (2012)
constructed dual antibody-conjugated MPIOs, targeting both
VCAM-1 and P-selectin (50:50 ratio). They did not show further
enhance contrast effects compared to single VCAM-1 antibody-
conjugated MPIOs in a model of acute inﬂammation in mice
(McAteer et al., 2012). Endothelial-Selectin (E-selectin) has also
been investigated in vitro using similar dual antibody-conjugated
MPIOs, targeting both VCAM-1 and E-selectin (Jefferson et al.,
2011).
Microsized particles of iron oxides are well-tolerated in mice,
with no short-term ill effects. Clearance experiments showed
that MPIOs are sequestered by the liver and spleen 24 h after
injection, with no evidence of adverse effects such as tissue infarc-
tion, inﬂammation, or hemorrhage. The MPIOs used so far in
experimental studies are non-biodegradable, due to their inert
coat. However, the basic iron contrast mechanism is potentially
transferable to humans with suitable adaptation of the surface
coat.
Their size similar to circulating platelets, their short blood
half-life and the exceptionally potent T2∗ MRI contrast effects
of targeted MPIOs, together with advancement of biocompatible
MPIOs, provide translational imaging opportunities for improved
diagnosis and treatment of endovascular inﬂammation in various
CNSdisorders. However, extensive toxicological proﬁling and syn-
thesis of sterile, clinical-grade targeted MPIOs according to good
manufacturing practice will be required before clinical translation
is feasible.
LAST AND FUTURE DEVELOPMENTS
To date, molecular MRI studies consisted primarily on proof-
of-concept studies reporting the feasibility to image a particular
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FIGURE 5 | Example of ultrasensitive molecular MRI of brain
inflammation using optimized MPIO-αVCAM-1. All the images
presented were acquired 20 min after MPIO-αVCAM-1 injection as
described by Montagne et al. (2012) and Gauberti et al. (2013).
Experimental autoimmune encephalomyelitis was induced by Myelin
oligodendrocyte glycoprotein (MOG) in C57BL6J mice. The T2∗-weighted
image presented is from a mouse with a clinical score of 3.
Intrastriatal injection of TNF (1 μg) was performed 24 h before imaging.
Intracerebral hemorrhage was induced by intrastriatal collagenase.
Carotid artery stenosis was performed by ligation of the right common
carotid artery. Ischemic stroke was induced by intra-arterial
administration of thrombin.
target. Very few studies used molecular MRI as a tool to investi-
gate brain–immune interactions. Reasons for this are numerous
including the lack of reliability of the imaging procedures with
the already mentioned false negative (mainly due to a lack of
sensitivity of most molecular MRI procedures) and false pos-
itive results (due to passive extravasation through an altered
BBB, endogenous contrast induced by microhemorrhages or
iron accumulation, inadequate post-processing analyses. . .). In
particular, most of the MRI contrast agents are described in
unique studies and no conﬁrmatory results in other models or
by other groups are presented. Altogether, these drawbacks lim-
ited the conﬁdence of the molecular imaging community in
molecular MRI and ﬁnally raised doubts about its feasibility.
Of note, the recent use of MPIO-based contrast agents dramat-
ically improved the reliability of molecular MRI and the latest
studies were able to provide new insights into brain immune
interactions.
For instance, numerous studies investigated the impact and
timing of leukocyte diapedesis after ischemic stroke. However,
the spatiotemporal modulation of the expression of adhesion
molecules by the brain endothelium after ischemic onset was
unknown. UsingMPIOs-αVCAM-1 inmice,wedemonstrated that
stroke induced overexpression of VCAM-1 (involved in mono-
cyte and T-Cell diapedesis) not only in the ischemic lesion, but
also in intact brain regions (Gauberti et al., 2013). In particular,
VCAM-1 overexpression was very strong in the close periph-
ery of the lesion. Using longitudinal imaging, we were able to
demonstrate that this overexpression was sustained for 5 days
after permanent ischemia (by electrocoagulation or permanent
thrombosis of the middle cerebral artery) but much quicker after
transient ischemia (Gauberti et al., 2014; Le Behot et al., 2014).
Interestingly, when VCAM-1 overexpression is sustained, the cor-
responding inﬂammatory region is recruited by the ischemic
core in a delayed fashion. Since this secondary lesion growth
can be blocked by anti-inﬂammatory treatments (such as cele-
coxib or high-dose statins) and by analogy with the ischemic
penumbra, we proposed the concept of inﬂammatory penum-
bra to describe this peri-lesional area overexpressing VCAM-1
(Figure 6). This pathophysiological concept is supported by other
studies demonstrating the critical role of VCAM-1 dependent
T-cells diapedesis in delayed lesion growth after ischemic stroke
(Liesz et al., 2011). In our study, the ability to simultaneously
and longitudinally observe VCAM-1 expression and ischemic
lesion development offered by molecular MRI was critical to
determine the fate of the inﬂammatory penumbra. In a clinical
setting, such imaging strategy may help to discriminate patients
who will experience malignant stroke characterized by an exacer-
bated inﬂammation (Vivien et al., 2011). Experimental studies on
the impact of peripheral inﬂammation on brain–immune inter-
actions also beneﬁted from molecular MRI. It is for instance
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FIGURE 6 | Schematic representation of the inflammatory penumbra
concept after ischemic stroke as revealed by MPIO-αVCAM-1
enhanced MRI. VCAM-1 overexpression is sustained and particularly
signiﬁcant in the peri-infarct area after ischemic stroke. From 24 h to
5 days post-stroke onset this inﬂammatory penumbra is recruited by the
ischemic core. Interestingly, anti-inﬂammatory treatments block this
secondary infarct expansion. In this context, the presence of an
inﬂammatory penumbra 24 h after stroke onset revealed by molecular
MRI of VCAM-1 may be used as a selection criteria for anti-inﬂammatory
treatment in stroke patients.
possible to reveal the impact of sepsis, acute hyperglycemia,
acute ethanol intoxication, or aging on brain endothelium expres-
sion of VCAM-1 using MPIO-based molecular MRI in mice
(Montagne et al., 2012). The exceptional sensitivity of the method
and its ease of use offer new avenues of investigations in the ﬁeld
of neuroinﬂammation.
Given the huge improvement in sensitivity and speciﬁcity
of molecular imaging of inﬂammation offered by MPIO-based
molecular MRI, efforts are ongoing to adapt this method for
clinical imaging. Indeed, currently usedMPIOs are not biodegrad-
able, especially because of their poly-urethane coating. Therefore,
the development of biodegradable and biocompatible MPIOs is
mandatory for further development of this imaging technology.
For instance, the production of multimeric magnetite particles
forming large MPIO-like particles which are biodegradable has
been described (Nkansah et al., 2011). Another active subject is
the impact of MPIO binding on endothelium physiology. Indeed,
several studies demonstrated outside-in signaling after binding
of leukocytes on ICAM-1 expressing endothelial cells. ICAM-1
clustering due to leukocyte binding triggers intra-cellular calcium
release and subsequent activation of RhoA and the formation of
actin stress ﬁlaments (Jefferson et al., 2013). Concerning VCAM-
1, a recent in vitro study demonstrated that MPIOs labeled with
VCAM-1 targeting antibodies do not promote endothelial inﬂam-
mation, in contrast to monocytes (Jefferson et al., 2013). However,
this potential side effect of targeted MPIOs should be tested for all
endothelial targets before clinical investigations. The risk of immu-
nization of the receiver of targeted MPIOs preparation must also
be studied and potentially counteracted using non-immunogenic
targeting moieties.
Besides toxicity issues, translation of MPIO-based molecular
MRI from bench to bedside will require the demonstration of the
feasibility to detect MPIOs using magnet at clinical ﬁeld strength
and using standard coils. Indeed, the sensitivity of MPIOdetection
depends both on the ﬁeld strength (higher ﬁeld strength would
produce larger susceptibility effect of the MPIOs) and on the spa-
tial resolution of the MRI acquisition. This last parameter would
be crucial to optimize for clinical translation since the resolu-
tion achieved in preclinical study is below 80 μm (isotropic) and
allows single MPIO imaging whereas the highest resolution of
3D T2∗-weighted images on clinical magnet is around 500 μm.
This lower resolution, because of partial volume effects, will lower
the sensitivity of the MRI acquisition to detect MPIOs. To over-
come this issue, longer acquisition times to increase the signal
to noise ratio and strengthen the T2∗-weighting will be nec-
essary and could limit the clinical availability of this method.
Interestingly, a whole brain 3D T2∗-weighted image with an
isotropic resolution of 500 μm can be acquired using a 7 Tesla
clinical magnet in 6 min with a high signal to noise ratio using
echo planar imaging (Zwanenburg et al., 2011). Such imaging
method with a clinically compatible acquisition time would be
particularly well suited for MPIO-based molecular MRI and argue
toward the feasibility of sensitive and timely molecular MRI in
humans. Studies in large animals such as non-human primates
are awaited to demonstrate the feasibility of MPIO-based imaging
in humans.
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CONCLUSION
While several years ago the feasibility of rapid and reliable molecu-
lar imaging of brain–immune interactions using MRI was elusive,
the mini-revolution represented by the development of MPIO-
based contrast agent has changed this view. Although molecular
MRI using targeted MPIOs still remains restricted to preclini-
cal imaging, studies aiming at closing the translational gap are
ongoing. Once available, such contrast agents will undoubtedly
help to improve our knowledge on the brain–immune interac-
tions taking place in the human brain after acute neurological
injury. Besides, they will represent potent tools to select patient
for anti-inﬂammatory treatment and subsequently monitor the
therapeutic response. Nevertheless, molecular MRI using targeted
MPIOs is limited to imaging of endothelial targets and does not
allow long term investigation of the fate of leukocyte once in the
brain parenchyma. To this aim, exogenous labeling of autolo-
gous cells and subsequent cell tracking using MRI remains the
method of choice. These two imaging strategies (i.e., targeted
MPIOs and MRI cell tracking) appear today as the most promis-
ing technologies to non-invasively study immune cells trafﬁcking
in both preclinical and clinical studies. These tools will help to
determine whether molecular MRI of brain–immune interactions
can improve the management of patients presenting acute brain
injury.
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